Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for prevention of acute kidney injury after coronary artery bypass graft surgery
IRCT20151227025726N21Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acetazolamide in acute kidney failure (AKF) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Incidence of acute kidney injury, Serum creatinine increase and 1 more. Started Mar 2020; status: completed.
02
Drugs
acetazolamide
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20151227025726N21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151227025726N21.